Hospitals
Physicians
Clinical trials
Contact us
Links
National Cancer Institute - Community Clinical Oncology Program

 

CURRENTLY OPEN CLINICAL TRIALS

Dayton Clinical Oncology Program accesses clinical trials through its membership in cooperative research groups funded by the National Cancer Institute (NCI), and through the pharmaceutical industry.

For a listing of research groups and links to their web sites, go to the "Links to Other Sites" tab at the left.

Clinical Trial By Disease Site
(Click the links to advance to a specific section)

   

 

Descriptions of these clinical trials are available on http://www.ClinicalTrials.gov



General Cancer Control Trials for Symptom Management

NRG-CC004

Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer

URCC-13059

Gap 70 + ;  A Geriatric Assessment Intervention For Patients Aged 70 And Over Receiving Chemotherapy For Advanced Cancer: Reducing Chemotherapy Toxicity In Older Adults 

Back to top

BRAIN

Glioblastoma:

A071102

Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Meningioma:

A071401

Trial Of SMO/AKT/Nf2 Inhibitors In Progressive Meningiomas With SMO/AKT/Nf2 Mutations

Metastases:

NRG-CC001

Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases

Back to list

Descriptions of these clinical trials are available on http://www.ClinicalTrials.gov

BREAST

BREAST CANCER CONTROL:

A011401

Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

A221405

A Study Evaluating The Pregnancy Outcomes And Safety Of Interrupting Endocrine
Therapy For Young Women With Endocrine Responsive Breast Cancer Who Desire
Pregnancy (Positive)

SCUSF-1102

A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics Services Among Breast Cancer Patients

WF97116

Trial Of Donepezil In Chemotherapy Exposed Breast Cancer Survivors With Cognitive Impairment

Back to list

HER2-

A011502

Trial of aspirin as adjuvant therapy for node-positive, HER2 negative breast cancer: the ABC trial

S1207

Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.

HER2-/BRACA+

NSABP B-55

Study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

HER2-/ER+

A011106

ALTernate approaches for Clinical Stage II or III Estrogen Receptor positive breast cancer Neo Adjuvant TrEatment (ALTERNATE) in postmenopausel women:

METASTATIC:

NRG-BR002

Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

S1501

Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

Nodal:

NRG-BR003

Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node- Positive or High-Risk Node-Negative Triple Negative Invasive Breast Cancer

NSABP B-51/RTOG 1304

Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Triple Negative

EA1131

Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following
Neoadjuvant Chemotherapy

S1416

Trial of Cisplatin with or without Veliparib in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.

S1418

Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative BreastCancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy

Back to list

 

Descriptions of these clinical trials are available on http://www.ClinicalTrials.gov

 

GASTROINTESTINAL:

 

Colorectal:

A021502

Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

NRG-GI004

Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

S1613

Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification

 

LIVER:

NRG-GI001

Focal Radiation Therapy For Unresectable, Localized Intrahepatic Cholangiocarcinoma

RTOG-1112

Study of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular Carcinoma

 

PANCREATIC:

EA2142

Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas

EA2161

Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)

S1505

Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma.

 

RECTAL:

NRG-GI002

Evaluation of Copanlisib (BAY 80-6946), (IND #130822), A Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations

N1048

Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Back to list

 

Descriptions of these clinical trials are available on http://www.ClinicalTrials.gov

 

GENITOURINARY:

BLADDER:

S1602

Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer

S1605

Trial of Atezolizumab in BCG-UnresponsiveNon-Muscle Invasive Bladder Cancer

 

PROSTATE:

NRG-GU002

Trial Of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or without Adjuvant Docetaxel

RENAL:

EA8143

Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

S1500

Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

 

Back to list

GYN:

Endometrial:

GOG-0286B Temporarily closed to accrual

Study Of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo As Initial Therapy For Measurable Stage III Or IVA, Stage IVB, or Recurrent Endometrial Cancer

Uterine:

GOG-0238

Trial Of Pelvic Irradiation With Or Without Concurrent Weekly Cisplatin In Patients With Pelvic-Only Recurrence Of Carcinoma Of The Uterine Corpus

Other:

NRG-GY005

Study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)

NRG-GY006

A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.

 

Descriptions of these clinical trials are available on http://www.ClinicalTrials.gov

HEAD and NECK

A091404

Study Of Enzalutamide For Patients With Androgen Receptor Positive Salivary Cancers

EA3132

Adjuvant Radiotherapy with or without Cisplatin for P53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)

LEUKEMIA:

ALL:

E1910

Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults

S1318

Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517) , Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL


LUNG:

A221401

Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes

NSCLC:

A151216 (ALCHEMIST)

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

A081105 (ALCHEMIST)

Study Of Erlotinib Or Placebo In Patients With Completely Resected Epidermal Growth Factor Receptor (EGRF) Mutant Non-Small Cell Lung Cancer (NSCLC)

E4512 (ALCHEMIST)

Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

EA5142 (ALCHEMIST)
A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
NRG-LU002
Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
S1403

Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)

S1507

Trial of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-Small Cell Lung Cancer and Progressive Disease Following One or Two Prior Systemic Therapies.

SCLC

NRG-CC003

Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

SQUAMOUS CELL

S1400

Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer

Descriptions of these clinical trials are available on http://www.ClinicalTrials.gov

LYMPHOMA:

S1608

Trial in Early Relapsing or Refractory Follicular Lymphoma.

 

Back to list

MELANOMA:

BRAFV600 Mutant

EA6134

Trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

S1320

Trial Of Intermittent Versus Continuous Dosing Of Dabrafenib (NSC-763760) And Trametinib (NSC-763093) In BRAF V600E/K Mutant Melanoma

Advanced

S1607

Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy

S1616

Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1Agent.

Unresectable

EA6141

Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

MYELOMA:

A061402

Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy.

E1A11

Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeoma

Back to list

Descriptions of these clinical trials are available on http://www.ClinicalTrials.gov

OTHER:

EAQ152

COMET - Communication and Education in Tumor Profiling: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer

EAY131

Molecular Analysis for Therapy Choice (MATCH)

Germ Cell

A031102

Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

Rare Tumors

S1609 confirmed rare cancer and/or cancer of unknown primary

DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

 

Descriptions of these clinical trials are available on http://www.ClinicalTrials.gov

 

QUESTIONS?

CONTACT DAYTON CLINICAL ONCOLOGY PROGRAM
OR ASK YOUR PHYSICIAN
"Is There a Clinical Trial For Me?"

Contact Us

By Phone:
(937) 775-1350
Fax:
(937) 775-1358
By Mail:
Dayton Clinical Oncology Program
3123 Research Blvd., Suite 150
Dayton, Ohio 45420